Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huato Wharton's jelly mesenchymal stem cell injection is an allogeneic cell therapy candidate developed by Shenzhen Boya Perception Pharmaceutical for the treatment of knee osteoarthritis. The product utilizes mesenchymal stem cells (MSCs) isolated from Wharton's jelly, the gelatinous tissue within the umbilical cord. These MSCs are characterized by their regenerative potential, including the ability to differentiate into chondrocytes and the secretion of paracrine factors that exhibit potent anti-inflammatory and immunomodulatory effects. Administered via a single intra-articular injection, the therapy is designed to modulate the joint microenvironment, alleviate pain, and potentially promote the repair of damaged articular cartilage in patients with degenerative joint disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huato Wharton's jelly mesenchymal stem cell injection.